Title: “Unmasking Hypersomnolence: Diagnostic Precision and Therapeutic Frontiers in NT1, NT2, and IH.”
Thursday, April 2, 2026 at 11:00am-12:30pm ET
Overview:
More than 20% of the population reports excessive sleepiness—but identifying when that sleepiness signals a hypersomnolence disorder remains a clinical challenge. How do we distinguish everyday fatigue from narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), or idiopathic hypersomnia (IH)?
Unmasking Hypersomnolence: Diagnostic Precision and Therapeutic Frontiers in NT1, NT2, and IH delivers a practical, clinician-focused playbook for improving recognition, diagnosis, and treatment. This webinar reviews key clinical features and diagnostic opportunities to better differentiate hypersomnolence disorders, with a deep dive into eliciting the full spectrum of cataplexy and applying evolving frameworks such as ICSD-3-TR and DSM-5-TR. Participants will gain actionable strategies to enhance diagnostic precision, individualize therapeutic approaches, and intervene earlier—while exploring emerging research and innovations shaping the rapidly evolving sleep medicine landscape
Learning Objectives:
- Clarify the Differential Diagnosis of Excessive Daytime Sleepiness
- Explore the Spectrum of Cataplexy Presentations
- Apply ICSD-3-TR Criteria for Central Disorders of Hypersomnolence
- Review Emerging Technology for NT1, NT2, and IH
- Introduce Emerging Diagnostic Technologies
Speakers:
Anne Marie Morse, DO, FAASM (Chair)
Nancy Foldvary-Schaefer, DO, MS
Nathaniel F. Watson, MD, MSc
The webinar is made possible by the SRS Foundation and supported by Takeda Pharmaceuticals.
Complimentary, Advanced Registration is Required. A recording will be available.
